Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyMeridian Actimmune prior auth coverage | OpenPayer
    Ask Trek AI about this page
    CurrentmeridianPolicy 366

    Actimmune (interferon gamma-1b) coverage

    Customize your policy alerts

    Sign up for meridian Policy 366 alerts

    Get alerted when Policy 366 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization policy for Actimmune covering FDA-approved indications and specific approval criteria for chronic granulomatous disease and malignant osteopetrosis; applies to Meridian Health Plan products requiring PA. Affects prescribers and patients seeking coverage for Actimmune.

    Policy Summary
    Payermeridian
    PolicyActimmune (interferon gamma-1b) coverage
    Policy CodePolicy 366
    Change TypeNo material changes
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review Date
    Key ActionSubmit prior authorization with diagnosis and required diagnostic documentation (e.g., molecular genetic test for CGD or radiographic imaging for malignant osteopetrosis).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1 yearcoverage duration for chronic indications noted
    All FDA-approvedindications stated
    Prescriber restrictionsspecialist prescriber requirement for CGD and osteopetrosis
    PA requiredpolicy list membership

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Actimmune (interferon gamma-1b) — Coverage Criteria & Product Entries

    Actimmune coverage criteria

    Approve when the following specific criteria are met for listed indications

    Chronic granulomatous disease (CGD): Approve if diagnosis has been established by a molecular genetic test identifying a gene‑related pathogenic variant linked to chronic granulomatous disease.

    Prescriber: prescribed by or in consultation with an immunologist, hematologist, or infectious disease specialist; coverage duration: 1 year

    Malignant osteopetrosis, severe: Approve if patient has radiographic (X‑ray) imaging demonstrating skeletal features consistent with malignant osteopetrosis.

    Prescriber: prescribed by or in consultation with an endocrinologist or hematologist; coverage duration: 1 year

    Other indications: All FDA‑approved indications are included; requests must include required medical information documenting the diagnosis.

    Authorization durations follow product guidance (chronic indications commonly 1 year)

    Initial Authorization — Covered when PA criteria are met

    Covered when PA criteria are met

    Prior authorization requirement: Prior authorization is required and approval is granted when the applicable PA Criteria and required medical information are provided.

    Authorization durations vary by product; many chronic approvals are for 1 year; some short courses (e.g., flucytosine) noted as 3 months

    Product-specific coverage criteria (sampled)

    Selected product coverage criteria as stated in the document

    Copiktra (CLL/SLL): Approve if patient has tried at least one Bruton tyrosine kinase inhibitor AND at least one venetoclax‑based regimen.

    Age 18+; authorization typically 1 year; provide prior therapy documentation

    Deferasirox: Approve for iron overload when serum ferritin level is documented and prescriber is or consulted with a hematologist; patient must be benefiting from therapy for continuation.serum ferritin documented

    Authorization 1 year

    Itraconazole (oral): Approve when itraconazole will be used orally; onychomycosis must be confirmed by a fungal diagnostic test (KOH, culture, or nail biopsy); ABPA primary treatment must be initiated with systemic corticosteroid concurrent therapy.

    Coverage durations vary by indication (e.g., disseminated/CNS 12 months, others 6 months)

    Product-specific coverage criteria (partial)

    Covered when product-specific criteria are met as summarized below

    Gomekli: Approve if patient meets indication‑specific diagnostic criteria and age restriction (e.g., 2 years and older where specified), with required documentation provided.age >=2 years where specified

    Authorization typically 1 year; provide diagnosis and required clinical documentation

    High‑risk medications (HRMs) general rules: Approve if prescriber documents assessment of risk versus benefit and any indication‑specific step‑therapy or prior trial requirements are met.

    Age‑based rules apply (e.g., patients >=65 may require additional criteria); authorization commonly 12 months

    Targeted oncology indications (sample)

    Alunbrig and several targeted oncology agents — examples of coverage criteria

    NSCLC — Alunbrig (example): Approve if patient has both: A) either (i) adjuvant therapy following tumor resection for tumors >= 4 cm or node‑positive disease, OR (ii) advanced or metastatic disease; AND B) ALK‑positive disease as detected by an approved test.

    Age and prescriber restrictions per product entries; provide ALK test result

    Anaplastic large cell lymphoma: Approve if patient has ALK‑positive disease AND (i) medication used for palliative‑intent therapy OR (ii) relapsed or refractory disease.

    Provide ALK test result and prior therapy history where applicable

    Arcalyst — initial and continuation therapy

    Arcalyst (rilonacept) indications and requirements

    Initial therapy — DIRA (Deficiency of IL‑1 receptor antagonist): Approve if confirmed bi‑allelic pathogenic variants in the IL1RN gene AND the patient had clinical benefit with anakinra subcutaneous injection.

    Prescriber: rheumatologist/geneticist/dermatologist or physician specializing in autoinflammatory disorders; initial authorization durations vary by indication (e.g., DIRA 6 months)

    Pericarditis — initial therapy: Approve for recurrent pericarditis when prescribed by an appropriate specialist and initial‑therapy criteria are met.

    Initial authorization 3 months for pericarditis; continuation requires positive response

    Continuation therapy: Approve continuation for any Arcalyst indication if patient had a positive clinical response to therapy.

    Continuation authorization typically 1 year

    Ambrisentan — diagnostic confirmation

    Ambrisentan (PAH) requirement

    PAH confirmation: Approve if diagnosis of pulmonary arterial hypertension (WHO Group 1) is documented with right‑heart catheterization results.

    Prescriber must be or consult with a cardiologist or pulmonologist; authorization for 1 year

    Arikayce — initial therapy criteria

    Arikayce (amikacin liposome) initial therapy for MAC lung disease

    Initial therapy — MAC lung disease: Approve if all of the following are met: A) positive sputum culture for Mycobacterium avium complex (any positive sputum after background multidrug regimen fulfills criterion), B) MAC isolate is susceptible to amikacin, and C) Arikayce will be used in combination with a background multidrug regimen (e.g., macrolide plus ethambutol plus a rifamycin).

    Prescriber: pulmonologist, infectious disease physician, or physician specializing in MAC lung infections; authorization 1 year

    Alpha1 PI replacement

    Alpha1‑proteinase inhibitor (Prolastin‑C) criteria

    Alpha1‑antitrypsin deficiency with emphysema: Approve if serum alpha1‑antitrypsin concentration is less than 80 mg/dL (11 micromol/L) AND diagnosis of emphysema/COPD is documented.<80 mg/dL

    Prescriber and documentation per product entry; authorization 1 year

    Augtyro (AUGTYRO) indications and criteria (partial)

    Covered when specified molecular and disease‑state criteria are met (excerpt):

    ROS1‑positive NSCLC (Augtyro): Approve if patient has locally advanced or metastatic non‑small cell lung cancer AND ROS1‑positive mutation detected by an approved test.

    Age restrictions apply per product entry (NSCLC 18+); provide ROS1 test result

    Augtyro - NTRK solid tumor and pediatric glioma criteria (partial)

    Covered when tumor NTRK fusion and disease extent meet criteria:

    Solid tumors with NTRK fusion: Approve if tumor is NTRK gene–fusion positive AND tumor is locally advanced or metastatic OR surgical resection would likely result in severe morbidity.

    Also covers NTRK‑positive pediatric diffuse high‑grade gliomas for adjuvant or recurrent/progressive use; age‑based limits apply

    Avmapki-Fakzynja (AVMAPKI-FAKZYNJA) criteria (partial)

    Covered when ALL of the following are met:

    Recurrent low‑grade serous ovarian/fallopian tube/primary peritoneal cancer (Avmapki‑Fakzynja): Approve if A) patient has recurrent low‑grade serous cancer; AND B) tumor has a KRAS mutation; AND C) patient has tried at least one systemic therapy.

    Age restriction 18+; provide prior systemic therapy documentation; authorization 1 year

    Ayvakit (AYVAKIT) criteria (partial)

    Covered when indication‑specific molecular or prior therapy criteria are met:

    GIST (Ayvakit): Approve if tumor is PDGFRA exon 18 mutation positive OR patient has tried two of the listed TKIs (imatinib, sunitinib, dasatinib, regorafenib, ripretinib).

    Age 18+; provide mutation or prior therapy documentation

    Myeloid/lymphoid neoplasms with eosinophilia: Approve if tumor is positive for PDGFRA D842V mutation.

    Provide molecular testing

    Systemic mastocytosis: Approve if platelet count >= 50,000/mcL AND patient has indolent or an advanced subtype listed.>= 50,000/mcL

    Provide platelet count and subtype documentation

    Balversa (BALVERSA) criteria (partial)

    Covered when disease and genetic alteration criteria are met:

    Urothelial carcinoma (Balversa): Approve if locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations AND disease progressed during or following prior platinum‑containing chemotherapy, other chemotherapy, or checkpoint inhibitor therapy.

    Age 18+; provide FGFR3 alteration and prior therapy documentation; authorization 1 year

    Pancreatic adenocarcinoma: Approve if FGFR genetic alteration present and disease is locally advanced/recurrent/metastatic when used as subsequent single‑agent therapy.

    Provide genetic testing and prior therapy history

    Benlysta (subcutaneous) criteria (partial)

    Covered when specified diagnostic and concurrent therapy conditions are met:

    Benlysta — SLE initial therapy: Approve if patient has autoantibody‑positive SLE (positive ANA and/or anti‑dsDNA) AND Benlysta is being used concurrently with at least one standard therapy (antimalarial, systemic corticosteroid, and/or other immunosuppressant) unless intolerant.

    Prescribed by or in consultation with a rheumatologist (initial); age restriction ≥5 years for initial therapy; authorization 1 year

    Benlysta — continuation: Approve continuation if Benlysta is used with at least one other standard therapy (unless intolerant) AND the patient has responded to Benlysta.

    Prescriber specialty per product entry; authorization 1 year

    Benlysta — lupus nephritis initial: Approve if diagnosis of biopsy‑confirmed lupus nephritis (e.g., WHO class III, IV, or V) AND Benlysta is used concurrently with an immunosuppressive regimen.

    Prescriber: nephrologist or rheumatologist; authorization 1 year

    Besremi (BESREMI) criteria (partial)

    Covered when FDA‑approved indications are met:

    Besremi — general: Authorize for FDA‑approved indications when required diagnosis documentation is provided; prescriber should be or consult with an oncologist/hematologist.

    Age restriction 18+; concomitant use with other interferon products is excluded; authorization 1 year

    Betaseron/Extavia criteria (partial)

    Covered when relapsing forms of multiple sclerosis are documented:

    Betaseron/Extavia — MS indications: Approve for relapsing forms of MS (clinically‑isolated syndrome, relapsing‑remitting, active secondary progressive) when prescribed by or after consultation with a neurologist or MS specialist.

    Exclusion: concurrent use with other MS disease‑modifying agents; authorization 1 year

    Bexarotene (oral and topical) criteria (partial)

    Covered when disease‑specific criteria and prescriber consultation are met:

    Oral bexarotene: Approve for FDA‑approved indications when prescribed by or in consultation with an oncologist or dermatologist; authorization 1 year.

    Provide diagnosis and prescriber documentation

    Topical bexarotene: Approve for cutaneous T‑cell lymphoma with cutaneous lesions, selected adult T‑cell leukemia/lymphoma subtypes, and primary cutaneous B‑cell lymphoma subtypes when used as skin‑directed therapy.

    Prescriber: oncologist or dermatologist; authorization 1 year

    Bexarotene (topical) — Coverage rules

    Covered when criteria below are met

    Bexarotene (topical) — coverage rules: Prescribed by or in consultation with an oncologist or dermatologist; approve for specified cutaneous lymphomas and subtypes as listed; authorization typically 1 year.

    See product entry for indication‑specific details

    Bosentan — Coverage rules

    Covered when ALL of the following are met

    Bosentan — PAH (WHO Group 1): Approve if diagnosis of pulmonary arterial hypertension (WHO Group 1) is confirmed by right‑heart catheterization and prescriber is or consulted with a cardiologist or pulmonologist.

    For CTEPH: patient must have tried Adempas, have a contraindication to Adempas, or be currently receiving bosentan; authorization 1 year

    Bosulif — Coverage rules

    Covered when ALL of the following are met

    Bosulif — criteria: Approve for listed hematologic neoplasms when diagnosis and required molecular markers or prior therapy history are documented (e.g., Ph‑positive/BCR::ABL1‑positive CML; age restrictions apply per indication).

    Authorization generally 12 months; prior therapy may be required for some indications

    Braftovi — Coverage rules

    Covered when ALL of the following are met

    Braftovi — criteria: Approve when diagnosis matches FDA‑approved indications and required BRAF V600 mutation status is documented; combination or prior therapy requirements apply per tumor type.BRAF V600 mutation where indicated

    Age 18+ for listed indications; authorization 1 year

    Brinsupri — Coverage rules

    Covered when ALL of the following are met

    Brinsupri — initial therapy (bronchiectasis, non‑CF): Approve if chest CT confirms bronchiectasis AND (for ages 12–17: >=1 pulmonary exacerbation in prior 12 months requiring antibiotics OR for >=18: >=2 pulmonary exacerbations in prior 12 months requiring antibiotics) AND respiratory symptoms are not primarily driven by COPD or asthma AND patient does not have cystic fibrosis.>=1 or >=2 exacerbations as age‑specified

    Prescriber: pulmonologist or infectious disease physician; authorization 1 year

    Brinsupri — continuation: Approve continuation if patient does not have cystic fibrosis AND experienced beneficial clinical response (e.g., reduced exacerbations, preserved lung function).

    Authorization 1 year

    Brukinsa — Coverage rules

    Covered when criteria specific to each hematologic malignancy are met

    Brukinsa — indication‑specific rules: Approve for the hematologic malignancy indications when the condition‑specific prior therapy and disease criteria are met (examples: follicular lymphoma after two prior systemic regimens when used with obinutuzumab; mantle cell lymphoma per listed prior therapy or TP53 mutation pathways).

    Age >=18 for most indications; authorization 1 year; provide prior therapy documentation

    Haegarda — Coverage rules

    Covered when ALL of the following are met

    Haegarda — HAE prophylaxis (Type I/II): Approve if HAE type I or II is confirmed by low functional C1‑INH protein (<50% of normal) AND low baseline serum C4 levels. For HAE with normal C1‑INH, approve if specific gene mutation is positive OR there is a family history and refractory disease to high‑dose antihistamines for >=1 month.functional C1‑INH <50%

    Prescriber: allergist/immunologist or clinician specializing in HAE; authorization 1 year

    Cabometyx — Coverage rules

    Covered when ALL of the following are met

    Cabometyx — indication‑specific rules: Approve when indication‑specific conditions are met (examples: RCC relapsed or stage IV; HCC previously treated with >=1 systemic therapy; GIST after specified prior agents; NSCLC with RET rearrangement progressed on first‑line RET inhibitors).

    Provide diagnosis, histology, RET status where applicable; authorization 1 year

    Cabometyx - Indication-specific authorization

    Cabometyx approvals are indication‑ and prior‑therapy‑dependent

    Cabometyx general: Approve if the member meets the specific prior‑therapy and disease criteria listed for the requested indication (see product entry for required prior regimens and molecular testing).

    Authorization duration 1 year; provide required prior therapy documentation

    Calquence - Indication-specific authorization

    Calquence (acalabrutinib) approvals

    Calquence indications: Approve for CLL/SLL; for mantle cell lymphoma approve if patient tried at least one systemic regimen or is not a candidate for systemic therapy; for marginal zone lymphoma and Waldenstrom approve if patient tried at least one systemic regimen.

    Authorization 1 year; prior therapy required for several indications

    Caprelsa - Indication-specific authorization

    Caprelsa (vandetanib) approvals

    Caprelsa indications: Approve for medullary thyroid carcinoma (MTC); for differentiated thyroid carcinoma approve if refractory to radioactive iodine therapy.

    Authorization 1 year

    Carglumic acid - Indication-specific authorization

    Carglumic acid approvals

    NAGS deficiency: Approve for N‑acetylglutamate synthase deficiency when genetic testing confirms a pathogenic mutation OR when hyperammonemia is present.

    Coverage duration: 3 months without genetic test; 12 months if genetic testing confirmed; other short‑term approvals 7 days

    PA/MMA acute hyperammonemia: Approve for propionic or methylmalonic acidemia with acute hyperammonemia if plasma ammonia >= 50 micromol/L and used with other ammonia‑lowering therapies.>= 50 micromol/L

    Provide plasma ammonia levels

    Cayston - Indication-specific authorization

    Cayston (aztreonam for inhalation) approvals

    Cayston: Approve when diagnosis is documented and prescribed by or in consultation with a pulmonologist, infectious diseases specialist, or cystic fibrosis specialist; relevant culture results (sputum, oropharyngeal, BAL) may be required.

    Authorization 1 year

    Clobazam - Indication-specific authorization

    Clobazam approvals

    Clobazam initial therapy: Approve for Lennox‑Gastaut initial therapy if patient tried or is concomitantly receiving one of listed antiseizure agents; for treatment‑refractory seizures approve if tried at least two other AEDs. Prescriber: neurologist for initial therapy.

    Age >=2 years for initial therapy; continuation requires prescriber confirmation of response; authorization 1 year

    Clomipramine - Indication-specific authorization

    Clomipramine approvals

    Clomipramine — OCD/Panic/Autistic or Depression pathways: Request must meet either: (1) prescribed for OCD, Panic Disorder, or Autistic disorder AND prior inadequate response/intolerance/contraindication to an SNRI or SSRI; OR (2) prescribed for Depression AND prior inadequate response/intolerance/contraindication to two agents among SNRIs, SSRIs, mirtazapine, or bupropion.

    Authorization 1 year; prior therapy required

    Product-specific coverage criteria (sampled)

    Selected product coverage criteria (as stated in the document):

    Sample — Copiktra: Approve for CLL/SLL only after required prior therapies are documented (see Copiktra entry).

    Coverage duration 1 year

    Sample — Cosentyx (plaque psoriasis): Approve if tried at least one traditional systemic agent for >=3 months unless intolerant OR has contraindication to methotrexate; a prior biologic (not Cosentyx) counts as trial.>=3 months

    Age‑specific restrictions apply; continuation requires clinical benefit

    Sample — Cystagon: Approve if diagnosis of nephropathic cystinosis is confirmed by genetic testing showing biallelic CTNS variants OR elevated WBC cystine concentration above lab reference.biallelic CTNS variants OR elevated WBC cystine

    Concomitant use with Procysbi is excluded; prescriber: nephrologist or metabolic disease specialist

    Deferasirox

    Covered when ALL of the following are met

    Deferasirox criteria: Approve when required medical information including serum ferritin is provided and prescriber is or consulted with a hematologist; continuation requires evidence of benefit.serum ferritin documented

    Authorization typically 1 year

    Diacomit (Dravet Syndrome)

    Initial and continuation therapy rules

    Diacomit — initial therapy: Approve for Dravet syndrome for patients 6 months and older when prescribed by or in consultation with a neurologist and documentation of diagnosis provided; initial therapy requires concomitant clobazam or documented inability to take clobazam.>=6 months

    Authorization 1 year

    Diacomit — continuation: Approve continuation if patient is responding to therapy as confirmed by prescriber.

    Authorization 1 year

    Dimethyl fumarate (Multiple Sclerosis)

    Covered when ALL of the following are met

    Dimethyl fumarate — indications: Approve for relapsing forms of multiple sclerosis (clinically‑isolated syndrome, relapsing‑remitting, active secondary progressive) when prescribed by or in consultation with a neurologist or MS specialist.

    Exclusion: concurrent use with other MS disease‑modifying agents; authorization 1 year

    Doptelet (Thrombopoietin receptor agonist)

    Covered when indication‑specific criteria are met

    Doptelet — thrombocytopenia with chronic liver disease (tablets): Approve if current platelet count <50 x 10^9/L AND patient is scheduled for a procedure within 10–13 days after starting therapy.<50 x 10^9/L

    Tablet formulation criteria; prescriber/hematologist consultation for chronic ITP initial therapy

    Doptelet — chronic ITP initial therapy: Approve if platelet count <30,000/mcL OR <50,000/mcL with increased bleeding risk AND patient tried one other therapy (e.g., systemic corticosteroids, IVIG, anti‑D, eltrombopag, romiplostim, fostamatinib, rituximab) or had splenectomy.

    Prescriber: hematologist for initial therapy; continuation requires beneficial clinical response

    Dupixent (by indication: AD, Asthma, COPD, CRSwNP, EoE, PN, CSU, Bullous Pemphigoid, AFRS)

    Covered when indication‑specific initial and continuation criteria are met

    Dupixent — Atopic dermatitis (AD) initial: Approve for indicated ages (initial therapy: 6 months and older) when prescribed by or in consultation with an allergist/immunologist or dermatologist.>=6 months for AD initial

    Continuation requires clinical benefit; authorization and durations vary by indication

    Dupixent — Asthma initial: Approve if A) blood eosinophils >=150 cells/µL within previous 6 weeks or oral corticosteroid–dependent asthma; B) patient uses ICS plus at least one additional controller; AND C) uncontrolled asthma as defined by exacerbation history or objective lung function criteria.>=150 cells/µL

    Prescriber: allergist/immunologist or pulmonologist; continuation requires clinical benefit

    Dupixent — COPD initial: Approve if blood eosinophils >=300 cells/µL within previous 6 weeks, patient received >=3 months combination therapy with at least two of LAMA/LABA/ICS, AND history of exacerbations as specified.

    Elrexfio

    Covered when ALL of the following are met

    Elrexfio criteria: Approve for adult patients (age 18+) when diagnosis and prerequisite systemic therapies are documented and therapy is prescribed by or in consultation with an oncologist.age >=18

    Prerequisite therapy required; authorization 1 year

    Emgality (migraine prevention)

    Covered when ALL of the following are met

    Emgality — initial therapy: Approve for patients aged 18+ who have >=4 migraine headache days per month prior to initiating preventive medication.>=4 days/month

    Exclusion: combination therapy with another cGRP inhibitor; authorization 1 year

    Emgality — continuation: If currently taking Emgality, approve continuation when the patient has demonstrated significant clinical benefit (examples: reduction in number of migraine days or severe migraine days).clinical improvement as defined by prescriber

    Authorization 1 year

    Emgality: Initial and continuation therapy

    Emgality (galcanezumab‑gnlm) coverage criteria

    Emgality initial therapy: Patient has ≥4 migraine headache days per month prior to initiating a migraine‑preventative medication.>=4 days/month

    Age ≥18; prescriber documents baseline migraine frequency

    Emgality continuation: If currently taking Emgality, continuation requires documented significant clinical benefit per prescriber (examples provided in product entry).clinical improvement

    Exclude concurrent cGRP inhibitor therapy

    Enbrel: Initial and continuation therapy

    Enbrel coverage criteria

    Enbrel initial therapy: Approve initial Enbrel when patient has tried one preferred adalimumab product (a trial of a non‑preferred adalimumab also counts) as required by indication; age and prescriber restrictions apply by indication.trial of 1 preferred adalimumab

    Continuation requires evidence of response; exclusion: concurrent biologic or targeted synthetic DMARD

    Enbrel continuation: Approve continuation when patient has had a clinical response to Enbrel.clinical response

    Some approvals may be through end of plan year

    Endari

    Endari coverage criteria

    Endari initial therapy: Approve if patient is ≥5 years of age and medication is prescribed by or in consultation with a sickle cell disease specialist.>=5 years

    Authorization 1 year

    Ensacove

    Ensacove coverage summary

    Ensacove: Approve for indicated adult oncology indications when diagnosis is documented; age 18+; authorization 1 year.>=18 years

    See product entry for indication specifics (e.g., NSCLC)

    Epidiolex

    Epidiolex coverage criteria

    Epidiolex initial therapy: Approve for patients ≥1 year of age when prescribed by or in consultation with a neurologist and diagnosis/prior therapies documented (syndrome‑specific requirements apply for Dravet, LGS, TSC).>=1 year

    Continuation requires clinical response; authorization 1 year

    Epoetin alfa

    Epoetin alfa coverage criteria

    CKD anemia (not on dialysis): Initial therapy approve if adult hemoglobin <10.0 g/dL (children ≤11 g/dL); continuation approve if currently on ESA and Hb ≤12.0 g/dL.adult Hb <10.0 g/dL; continuation ≤12.0 g/dL

    Indication‑specific thresholds and prescriber documentation required

    Chemotherapy‑induced anemia: Approve if patient is receiving myelosuppressive chemotherapy for non‑curative treatment and initial Hb <10.0 g/dL; continuation if currently on ESA and Hb ≤12.0 g/dL.Hb <10.0 g/dL initial

    Prescriber and laboratory values required

    Anemia in dialysis patients: Anemia in patients with chronic renal failure on dialysis is not covered under Medicare Part D (administrative billing exclusion).

    Claims should be submitted under ESRD bundled payment benefit per policy

    Erivedge

    Erivedge coverage criteria

    Locally advanced basal cell carcinoma (new to therapy): Approve if recurrent following surgery or radiation OR patient is not a candidate for surgery or radiation.

    Authorization 1 year

    Other Erivedge approvals: Approve for metastatic BCC and specific CNS tumor indications (e.g., medulloblastoma with SHH mutation after prior chemotherapy) when criteria are met.

    Provide prior therapy and mutation documentation where applicable

    Erleada

    Erleada coverage criteria

    Prostate cancer indications: Approve for non‑metastatic castration‑resistant and metastatic castration‑sensitive prostate cancer when used with androgen deprivation therapy or in patients post‑orchiectomy.

    Age 18+; authorization 1 year

    Erleada

    Erleada

    Erleada coverage: Authorizations: 1 year; Approve for FDA‑approved prostate cancer indications when used with androgen deprivation therapy or in patients with bilateral orchiectomy.

    Age 18+

    Erlotinib

    Erlotinib

    Erlotinib — EGFR mutation‑positive NSCLC: Approve if patient has EGFR mutation‑positive non‑small cell lung cancer as detected by an approved test (examples: exon 19 deletions, exon 21 L858R, L861Q, G719X, S768I).

    Provide EGFR mutation test result; authorization 1 year

    Erlotinib — other indications: Approve for other FDA‑listed indications (e.g., RCC combined with bevacizumab, chordoma after prior therapy, pancreatic cancer with gemcitabine) when product‑specific criteria are met.

    Provide indication‑specific documentation

    Everolimus

    Everolimus

    Everolimus — breast cancer (HR+, HER2‑): Approve if recurrent/metastatic HR+, HER2‑ disease AND prior endocrine therapy trial AND intended combination therapy criteria are met and no disease progression while on everolimus.

    Provide HER2/HR status and prior therapy documentation; authorization 1 year

    Everolimus — other indications: Approve for multiple other oncology and TSC indications when indication‑specific prior therapy and diagnostic criteria are documented (see product entry).

    Authorization 1 year

    Fabrazyme

    Fabrazyme

    Fabrazyme coverage: Approve if laboratory demonstrates deficient alpha‑galactosidase A activity in leukocytes or fibroblasts OR molecular genetic test shows a pathogenic GLA variant.

    Prescriber: geneticist, endocrinologist, metabolic disorder specialist; exclusion: concurrent use with Galafold or Elfabrio; authorization 1 year

    Fasenra

    Fasenra

    Fasenra (CMS review entry): This product's detailed criteria, exclusions, required medical information, age/prescriber restrictions, and coverage duration are under CMS review in the source document.

    Refer to product entry once CMS review details are finalized

    Fingolimod

    Fingolimod

    Fingolimod coverage: Approve for relapsing forms of multiple sclerosis (clinically‑isolated syndrome, relapsing‑remitting, active secondary progressive) when prescribed by or in consultation with a neurologist or MS specialist.

    Age 10+; exclusion: concurrent use with other MS disease‑modifying agents; authorization 1 year

    Fintepla

    Fintepla

    Fintepla — Dravet and LGS indications: Initial therapy: age and prior‑therapy requirements per indication (e.g., Dravet initial: age ≥2 and tried or concomitantly receiving at least two other AEDs or specific alternatives); continuation approve if responding to therapy.age >=2 for Dravet initial

    Prescriber: neurologist for initial therapy; authorization 1 year

    Firmagon

    Firmagon

    Firmagon coverage: Approve for FDA‑approved indications when prescribed by or in consultation with an oncologist; Part B versus Part D determination made at time of PA.

    Authorization and duration per product entry; typically 1 year

    Flucytosine

    Flucytosine

    Flucytosine coverage: Covered for medically‑accepted indications when PA criteria are met and required documentation is provided.

    Coverage duration noted as 3 months in the excerpt

    Initial Authorization

    Covered when PA criteria are met

    Initial Authorization — PA criteria: Prior authorization required; providers must supply required medical information as requested in the PA process.

    Some approvals have short durations (e.g., flucytosine 3 months); many chronic approvals 1 year

    Product-specific coverage criteria (partial)

    Covered when product‑specific criteria are met as summarized below

    Gomekli: Approve for indicated neurofibromatosis type 1 patients (e.g., symptomatic plexiform tumors) with required documentation; age restrictions and prescriber requirements per product entry.age >=2 where specified

    Authorization typically 1 year

    Eligard / leuprolide (oncology): Approve for prostate and other oncology indications when prescribed by or in consultation with an oncologist or urologist and indication‑specific criteria are met.

    Authorization 1 year; specific off‑label head and neck salivary gland tumor criteria noted for Eligard

    Growth hormone products (Omnitrope etc.): Approve when diagnostic and testing criteria for GH deficiency or other covered indications are met (stimulation test thresholds, pituitary hormone deficits, growth velocity criteria as specified).multiple numeric thresholds per product entry

    Benzodiazepines and related HRMs - anxiety and general rules

    Covered when criteria below are met

    HRM general approval: Prescriber must confirm they assessed risk versus benefit and elect to initiate/continue a high‑risk medication.

    Patients <65 generally approved; patients >=65 require additional criteria per product

    Anxiety management (benzodiazepine example): For anxiety, either concurrent short‑term use with an SSRI/SNRI until the SSRI/SNRI is effective OR prior inadequate response/intolerance/contraindication to at least two agents from SSRI or SNRI classes is required.

    Procedure‑related sedation limited to 1 month for some agents

    Cyproheptadine - rhinitis

    Covered when ALL of the following are met

    Cyproheptadine — rhinitis: Approve if patient tried and had inadequate response or intolerance to two non‑HRM alternatives (levocetirizine, azelastine nasal, fluticasone nasal, or flunisolide nasal).2 alternatives failed

    Prescriber documents prior trials; age‑based rules apply

    First-generation antihistamines (hydroxyzine, promethazine)

    Covered when ALL of the following are met

    First‑generation antihistamines (hydroxyzine, promethazine): Approve when prescriber confirms risk/benefit and required prior trials are met: for promethazine in emesis the patient tried an oral prescription antiemetic; for hydroxyzine in rhinitis or anxiety, prior trials of specified non‑HRM alternatives required.prior trials as specified

    Patients >=65 have additional criteria; authorization typically 12 months

    Phenobarbital - seizures

    Covered when ALL of the following are met

    Phenobarbital — seizures: For treatment of seizures, approve only if patient is currently taking phenobarbital and prescriber has assessed risk versus benefit prior to approval.

    Coverage not provided for sedation/insomnia use; authorization 12 months

    Other HRMs (scopolamine, cyclobenzaprine, temazepam)

    Covered when ALL of the following are met

    Other HRMs (scopolamine, cyclobenzaprine, temazepam): Approve when prescriber confirms risk versus benefit and any indication‑specific prior‑therapy requirements are met.

    Authorization often 12 months; see product entries for indication specifics

    Indications: Approve for FDA‑approved and selected medically‑accepted indications when product‑specific criteria are satisfied.

    Provide required documentation per product entry

    Specialty oncology agents (Hyrnuo, Ibrance, Ibtrozi)

    Covered when product‑specific criteria are met

    Specialty oncology agents — general: Approve when age and diagnosis criteria are met and required diagnostic or molecular testing and prior therapy history are provided (examples: Ibrance, Hyrnuo, Ibtrozi).age >=18 where specified

    Authorization typically 1 year; provide histology/mutation testing and prior therapy documentation

    Ibrance — breast cancer criteria: Approve for HR+, HER2‑ locally advanced or metastatic breast cancer when the patient meets specified menopausal/sex and concomitant therapy conditions (e.g., postmenopausal combined with aromatase inhibitor or fulvestrant; pre/perimenopausal with ovarian suppression and appropriate combination), per product entry.

    Provide hormonal status and planned concomitant therapy

    Ibtrozi - Covered when ALL are met

    Ibtrozi

    Ibtrozi approval criteria: Patient is 18 years or older AND has ROS1‑positive non‑small cell lung cancer as detected by an approved test AND meets the applicable FDA‑approved indication.

    Authorization typically 1 year; provide ROS1 test result

    Icatibant - Covered when ANY listed criteria met

    Icatibant - Hereditary Angioedema (HAE)

    Icatibant initial or repeat therapy: Initial therapy: approve for HAE type I or II when low functional C1‑INH (<50% of normal) AND low baseline serum C4 per lab reference are documented; OR approve for patients with prior favorable clinical response to icatibant for repeat use; approve for HAE with normal C1‑INH (Type III) for acute attacks as specified.functional C1‑INH <50%

    Authorization typically 1 year; provide lab values or prior response documentation

    Iclusig - Covered when ANY indication-specific criteria met

    Iclusig

    Iclusig approvals by indication: Approve for indications contingent on disease‑ and mutation‑specific criteria (e.g., T315I status, prior TKI trials, Ph‑positive/BCR::ABL1 reporting) as documented per product entry.

    Authorization 1 year; provide Ph/T315I status where applicable

    Idhifa - Covered when ALL are met

    Idhifa

    Idhifa approval criteria: Patient is 18 years or older AND has AML with positive IDH2‑mutation status as detected by an approved test.

    Authorization 1 year; provide IDH2 mutation test result

    Imatinib - Covered when ALL are met

    Imatinib / Imkeldi

    Imatinib general requirements: Approve when diagnosis is provided and, for CML/ALL, Philadelphia chromosome (Ph) or BCR::ABL1 status is reported; indication‑specific prior therapy or mutation criteria apply (e.g., PDGFR rearrangements, activating KIT mutations).

    Authorization typically 1 year; Imkeldi approvals require specific administration methods per labeling

    Imbruvica - Covered when ANY listed criteria met

    Imbruvica

    Imbruvica approvals by indication: Approve for multiple hematologic indications when the indication‑specific prior therapy and disease criteria are met (examples: CLL, GVHD after conventional therapy, B‑cell lymphoma after prior regimens).

    Age and prior therapy requirements vary by indication; authorization 1 year

    This policy requires prior authorization for Actimmune (interferon gamma-1b). Approvals are available for All FDA‑approved indications when the specified criteria are met. For the two condition‑specific indications excerpted here, coverage is authorized when diagnostic confirmation is provided: approve chronic granulomatous disease (CGD) if the diagnosis is established by a molecular genetic test identifying a gene‑related pathogenic variant linked to CGD; approve severe malignant osteopetrosis if radiographic (X‑ray) imaging demonstrates skeletal features consistent with malignant osteopetrosis. Authorization duration for these chronic indications is typically 1 year. Prescriber speciality requirements apply: CGD requests should be prescribed by or in consultation with an immunologist, hematologist, or infectious disease specialist; malignant osteopetrosis requests should be prescribed by or in consultation with an endocrinologist or hematologist. No specific exclusion criteria are listed in this excerpt.

    Affected Products & Coding (excerpted)

    Listed products (no billing codes provided in this excerpt)mixed
    No codes listed
    Listed productsmixed
    bexarotenebexarotene
    Listed productsmixed
    bosentanbosentan oral tablet
    Listed productsmixed
    BosulifBosulif
    Listed productsmixed
    BraftoviBraftovi
    Listed productsmixed
    BrinsupriBrinsupri
    Listed productsmixed
    BrukinsaBrukinsa
    Listed productsmixed
    HaegardaHaegarda
    Listed productsmixed
    CabometyxCabometyx
    Products listed in this segmentmixed
    clorazepate dipotassiumclorazepate dipotassium
    Diazepam IntensolDiazepam Intensol
    diazepam oraldiazepam oral
    cyproheptadinecyproheptadine oral tablet
    hydroxyzine HClhydroxyzine HCl oral tablet
    hydroxyzine pamoatehydroxyzine pamoate oral capsule
    promethazinepromethazine oral
    phenobarbitalphenobarbital
    scopolamine basescopolamine base
    cyclobenzaprinecyclobenzaprine oral tablet
    1–10 of 14
    1/2
    Products Affectedmixed
    No codes listed
    inv-125: Alpha1-antitrypsin serum concentration — numeric threshold
    Alpha1-antitrypsin serum concentrationSerum concentration < 80 mg/dL (or 11 micromol/L) required for alpha1‑antitrypsin deficiency with emphysema
    Associated indicationDiagnosis of emphysema/COPD with alpha1‑antitrypsin deficiency
    Authorization duration1 year when criteria met
    Age/prescriber restrictionPrescribed for adults (age 18+) per product entry

    Prior Authorization, Documentation & Denial Triggers

    Prior Authorization

    Prior authorization required; 1-year approvals for CGD and malignant osteopetrosis

    Prior authorization is required for Actimmune and many listed products; approvals for chronic granulomatous disease (CGD) and malignant osteopetrosis may be granted for 1 year when criteria are met.

    Prior Authorization

    PA criteria required; typical 1-year authorization

    Submit a prior authorization request that documents the diagnosis and any indication-specific prerequisites; many agents authorize for 1 year when PA criteria are met.

    • Provide diagnosis and required supporting test results where specified
    • Authorization durations commonly set to 1 year
    Prior Authorization

    PA required for specialty products; approvals typically 1 year

    Key Definitions & Diagnostic Thresholds

    inv-273: Chronic granulomatous disease (CGD) — molecular genetic test requirement for approval
    Molecular genetic test requiredApproval for chronic granulomatous disease requires a molecular genetic test identifying a gene‑related pathogenic variant
    PrescriberPrescribed by or in consultation with an immunologist, hematologist, or infectious disease specialist
    Coverage duration1 year
    inv-274: Malignant osteopetrosis, severe — radiographic imaging requirement
    Radiographic imaging requiredApproval for malignant osteopetrosis requires radiographic (X‑ray) imaging demonstrating skeletal features consistent with the disease
    PrescriberPrescribed by or in consultation with an endocrinologist or hematologist

    Policy Background & Scope

    Actimmune (interferon gamma‑1b) is addressed by this prior authorization policy for Meridian Health Plan products. Coverage is limited to FDA‑approved indications, with specific approval rules for chronic granulomatous disease (CGD) and severe malignant osteopetrosis. For CGD, approval requires documentation of a pathogenic gene‑related variant identified by a molecular genetic test; for malignant osteopetrosis, approval requires radiographic (X‑ray) imaging demonstrating the characteristic skeletal features. Prescriber restrictions apply: CGD requests should be prescribed by or in consultation with an immunologist, hematologist, or infectious disease specialist; malignant osteopetrosis requests should be prescribed by or in consultation with an endocrinologist or hematologist. When criteria are met, authorizations are typically granted for 1 year. This policy applies to Meridian Health Plan products that require prior authorization.

    Policy Summary
    Payermeridian
    PolicyActimmune (interferon gamma-1b) coverage
    Policy CodePolicy 366
    Change TypeNo material changes
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review Date
    Key ActionSubmit prior authorization with diagnosis and required diagnostic documentation (e.g., molecular genetic test for CGD or radiographic imaging for malignant osteopetrosis).
    SourceLink
    On This Page
    Actimmune (interferon gamma-1b) — Coverage Criteria & Product EntriesAffected Products & Coding (excerpted)Prior Authorization, Documentation & Denial TriggersKey Definitions & Diagnostic ThresholdsPolicy Background & Scope
    >=300 cells/µL

    Prescriber: allergist/immunologist or pulmonologist

    Dupixent — EoE initial: Approve if weight >=15 kg AND endoscopic biopsy shows >=15 intraepithelial eosinophils per HPF AND no secondary cause AND Rx‑strength PPI trial for >=8 weeks.>=15 eosinophils/HPF

    Prescriber: allergist or gastroenterologist; continuation requires benefit after 6 months

    Refer to detailed product criteria for stimulation test cutoffs and age‑specific thresholds

    High‑risk medications (benztropine, benzodiazepines) — example rules: Approve when prescriber confirms risk/benefit assessment and indication‑specific step‑therapy or prior‑trial criteria are met; age‑based restrictions apply (patients >=65 may require additional criteria).

    Coverage durations commonly 12 months for HRMs; see product entries for anxiety and other indication specifics

    inv-126: Pulmonary exacerbations in last 12 months — numeric thresholds by age for Brinsupri
    Pulmonary exacerbations (ages 12–17)>= 1 pulmonary exacerbation in prior 12 months that resulted in an antibiotic prescription
    Pulmonary exacerbations (>=18 years)>= 2 pulmonary exacerbations in prior 12 months that resulted in antibiotic prescriptions
    Imaging requirementHistory of bronchiectasis diagnosed by chest CT required
    ExclusionPatient must NOT have cystic fibrosis
    PrescriberPrescribed by or in consultation with pulmonologist or infectious disease physician
    inv-127: Functional C1-INH protein — threshold for HAE diagnosis
    Functional C1-INH protein thresholdFunctional C1‑INH protein less than 50% of normal at baseline required to confirm HAE type I or II
    Supporting labLow baseline serum C4 level also required
    UseRequired for HAE prophylaxis approvals (Haegarda)
    Authorization duration1 year when criteria met
    inv-128: Plasma ammonia — threshold for carglumic acid acute treatment
    Plasma ammonia thresholdPlasma ammonia >= 50 micromol/L required for acute treatment of PA/MMA-related hyperammonemia with carglumic acid
    IndicationsPropionic acidemia (PA) or methylmalonic acidemia (MMA) with hyperammonemia (acute) — use with other ammonia‑lowering therapies
    Coverage duration notesAcute approvals typically 7 days; genetic-test confirmed NAGS may authorize longer (3–12 months per entry)
    PrescriberPrescribed by or in consultation with metabolic disease specialist
    inv-129: Blood eosinophil counts — Dupixent asthma/COPD thresholds
    Dupixent — Asthma blood eosinophil threshold>= 150 cells/μL within the previous 6 weeks (or prior to Dupixent/another mAb) required for asthma criteria
    Dupixent — COPD blood eosinophil threshold>= 300 cells/μL within the previous 6 weeks required for COPD criteria
    TimingEosinophil count must be within previous 6 weeks or prior to starting Dupixent/other monoclonal antibody
    Required documentationDiagnosis and eosinophil laboratory result must be provided with PA request
    inv-130: Migraine frequency — Emgality threshold
    Emgality — minimum migraine frequency>= 4 migraine headache days per month prior to initiating a migraine‑preventive medication (required for initiation)
    Age restrictionAge 18 years and older for Emgality initiation
    Continuation requirementIf currently on Emgality, documentation of significant clinical benefit (examples: reduction in migraine days) required for continuation
    inv-131: Eosinophils in EoE biopsy — biopsy threshold
    EoE biopsy threshold>= 15 intraepithelial eosinophils per high‑power field on endoscopic biopsy required for EoE criteria (Dupixent)
    Weight requirementPatient weight >= 15 kg for Dupixent EoE initial therapy
    Other requirementsExclude secondary causes and trial of RX‑strength PPI for >= 8 weeks prior to approval
    inv-132: Migraine headache days per month — Emgality numeric threshold
    Emgality numeric threshold (migraine days)>= 4 migraine headache days per month prior to initiating preventive therapy
    Documentation requiredNumber of migraine headaches per month must be provided with PA request
    Continuation evidenceContinuation requires documented significant clinical benefit if already on therapy
    inv-133: Hemoglobin thresholds (examples) — epoetin alfa
    Hemoglobin threshold — CKD initialInitial therapy for CKD (not on dialysis): adult Hb < 10.0 g/dL (children <=11 g/dL)
    Hemoglobin threshold — continuationContinuation therapy if currently on ESA: Hb <= 12.0 g/dL
    Chemotherapy-induced anemiaInitial therapy: Hb < 10.0 g/dL when receiving myelosuppressive chemotherapy for non‑curative treatment
    Dialysis patientsAnemia in dialysis patients is managed outside Medicare Part D per policy guidance (administrative/billing note)
    inv-134: Minimum age examples — various products
    Endari minimum ageEndari (glutamine) — age >= 5 years required for initial therapy
    Epidiolex minimum ageEpidiolex — age >= 1 year required for initial therapy
    Emgality minimum ageEmgality — age >= 18 years required for migraine prevention (initiation)
    Prescriber notesSome products require specialist prescriber or consultation for initial authorization (entries specify per product)

    Prior authorization is required for listed specialty products; approvals are typically for 1 year and contingent on meeting product-specific criteria (diagnosis, age, prescriber, mutation or prior therapy requirements).

    Prior Authorization

    Copiktra PA — prerequisite therapy documented; 1-year coverage

    Copiktra requests require prior authorization and must document prior therapy: at least one Bruton tyrosine kinase inhibitor and at least one venetoclax-based regimen for CLL/SLL; coverage duration is 1 year.

    • Document prior BTK inhibitor (e.g., ibrutinib, zanubrutinib, acalabrutinib, pirtobrutinib)
    • Document prior venetoclax-based regimen
    Prior Authorization

    Cosentyx PA — indication- and prior-therapy–dependent

    Cosentyx requires prior authorization; initial and continuation approvals depend on indication-specific prior therapy and evidence of benefit (e.g., prior trial of traditional systemic agent for plaque psoriasis).

    • For plaque psoriasis: document trial of at least one traditional systemic agent for ≥3 months unless intolerant
    • Continuation requires documented clinical benefit
    Prior Authorization

    Deferasirox PA — serum ferritin and hematology prescriber required

    Deferasirox requires prior authorization and documentation of a serum ferritin level; the medication must be prescribed by or in consultation with a hematologist and approvals are typically for 1 year.

    • Include current serum ferritin level with the PA request
    • Prescriber must be a hematologist or consult a hematologist
    Prior Authorization

    Diacomit PA — age and neurologist prescriber required

    Diacomit requires prior authorization; initial therapy is limited to patients 6 months and older and must be prescribed by or in consultation with a neurologist for initial therapy; authorization is for 1 year.

    • Document diagnosis of Dravet syndrome
    • Prescriber must be a neurologist or consult with one
    Prior Authorization

    Dimethyl fumarate PA — neurologist/MS specialist prescriber

    Dimethyl fumarate requires prior authorization; prescriber must be a neurologist or MS specialist and authorization will be for 1 year when criteria for relapsing forms of MS are documented.

    • Provide documentation of relapsing form of multiple sclerosis
    • Prescriber must be or consult with a neurologist/MS specialist
    Prior Authorization

    Doptelet PA — hematology consultation and therapy prerequisites

    Doptelet requests require prior authorization with age- and formulation-specific restrictions; chronic ITP initial therapy must be prescribed by or after consultation with a hematologist and document prior therapy as specified.

    • For chronic ITP initial therapy: document platelet count and trial of one other therapy (e.g., systemic corticosteroids, IVIG, anti‑D, eltrombopag, romiplostim, fostamatinib, rituximab) or prior splenectomy
    • Prescriber must be or consult with a hematologist for initial therapy
    Prior Authorization

    Dupixent PA — detailed indication-specific documentation required

    Dupixent requires prior authorization; submit indication-specific documentation (diagnosis and required clinical measures) and prescriber specialty/consultation where specified; initial and continuation criteria vary by indication.

    • Provide diagnosis and required objective measures per indication (e.g., eosinophil counts, biopsy, symptom duration)
    • Prescriber should be or consult with specified specialist (allergist/immunologist, dermatologist, pulmonologist, or gastroenterologist as indicated)
    Prior Authorization

    Emgality PA — age ≥18 and ≥4 migraine days/month; 1-year coverage

    Emgality prior authorization is required for adults (≥18 years); initial therapy requires documentation of ≥4 migraine headache days per month prior to initiating preventive therapy and coverage is for 1 year.

    • Document patient age ≥18 years
    • Document ≥4 migraine headache days per month prior to initiation
    Prior Authorization

    Enbrel PA — trial of preferred adalimumab product required

    Enbrel initial therapy requires a trial of one preferred adalimumab product (a trial of a non-preferred adalimumab also counts) before approval; continuation requires evidence of response.

    • Document trial of one preferred (or non-preferred) adalimumab product
    • Provide evidence of clinical response for continuation
    Prior Authorization

    Fingolimod PA — neurologist/MS specialist prescriber required

    Fingolimod requires prior authorization and the prescriber must be a neurologist or consult with a neurologist/MS specialist; approval applies to relapsing forms of MS.

    • Provide diagnosis of a relapsing form of multiple sclerosis
    • Prescriber must be or consult with a neurologist or MS specialist
    Prior Authorization

    PA duration may be 3 months where specified by criteria

    Some prior authorizations are limited to shorter durations per the criteria; when specified in the product entry, authorization duration may be 3 months.

    • Confirm requested coverage duration matches PA criteria (e.g., 3 months where stated)
    Prior Authorization

    Itraconazole PA — oral use and fungal diagnostic confirmation required

    Itraconazole oral capsule requires prior authorization and diagnostic confirmation for onychomycosis (KOH, fungal culture, or nail biopsy) when used for tinea unguium; include evidence that the drug will be used orally.

    • Provide fungal diagnostic test result (KOH preparation, fungal culture, or nail biopsy) for onychomycosis
    • Document intended oral route of administration
    Prior Authorization

    Ivermectin PA — diagnosis-specific criteria; 30-day coverage

    Ivermectin oral requires prior authorization; approval criteria include specific diagnoses (e.g., pediculosis or scabies) and coverage duration is 30 days.

    • Document diagnosis consistent with listed indications (e.g., head/body/pubic lice, classic or crusted scabies)
    • Note coverage duration: 30 days
    Prior Authorization

    IVIG PA — prior authorization required; 12-month authorization when approved

    IVIG (Gamunex-C) requires prior authorization; when approved, authorization will be for 12 months and include the required medical information as listed.

    • Provide required medical information and indication details
    • Be prepared for Part B vs D determination per CMS guidance when applicable
    Prior Authorization

    Jynarque PA — nephrologist prescriber and renal function documentation; 1-year coverage

    Jynarque (tolvaptan) requires prior authorization; prescriber must be a nephrologist or consult with one, renal function must be documented, and the patient must not currently be receiving another tolvaptan product; coverage is for 1 year.

    • Document diagnosis of rapidly-progressing ADPKD and renal function
    • Confirm patient is not currently receiving another tolvaptan product
    • Prescriber must be or consult with a nephrologist
    Step Therapy

    Alunbrig step therapy — prior ALK inhibitor trial required

    Alunbrig requires a prior trial of specific ALK inhibitors (Alecensa, Ensacove, or Lorbrena) for patients new to therapy for NSCLC before approval.

    • Document trial of Alecensa, Ensacove, or Lorbrena prior to Alunbrig initiation for NSCLC
    Step Therapy

    Prior systemic therapy required for selected oncology indications

    Some oncology indications require prior systemic therapy trials before approval (examples include Avmapki-Fakzynja and other targeted agents); document prior systemic regimens as specified.

    • Provide documentation of prior systemic therapy trials when required by the product-specific criteria
    Step Therapy

    Bosentan step therapy for CTEPH — Adempas trial required unless contraindicated

    For CTEPH, bosentan step therapy requires the patient to have tried Adempas, have a contraindication to Adempas, or be currently receiving bosentan.

    • Document trial of Adempas or contraindication to Adempas, or confirm current bosentan use
    Step Therapy

    Braftovi — combination/sequence requirements for colorectal indications

    Braftovi coverage for certain colorectal cancer indications requires combination or sequence use with cetuximab/panitumumab and FOLFOX or prior chemotherapy per indication-specific criteria.

    • Document combination regimen (e.g., with cetuximab/panitumumab and FOLFOX) or prior chemotherapy as specified
    Step Therapy

    Cabometyx — prior systemic therapy required per indication

    Cabometyx approvals require prior therapy per indication (e.g., prior sorafenib or lenvatinib for hepatocellular carcinoma); document prior systemic therapies as applicable.

    • Provide prior systemic therapy history per the indication (e.g., sorafenib or lenvatinib for HCC)
    Step Therapy

    Doptelet prerequisite therapy — trial of one other ITP therapy required

    For chronic ITP, initial Doptelet therapy requires trial of one other therapy (e.g., systemic corticosteroids, IVIG, anti‑D, eltrombopag, romiplostim, fostamatinib, rituximab) or prior splenectomy before approval.

    • Document prior trial of at least one listed therapy or prior splenectomy
    Step Therapy

    Step therapy for high-risk medications — alternatives tried and prescriber risk/benefit confirmation

    High-risk medications (HRMs) listed require prior trials or intolerance of specified alternative non‑HRM agents before approval; prescriber must confirm risk vs benefit.

    • Document trials or intolerance of specified alternatives per HRM entry
    • Prescriber must attest that risk versus benefit has been assessed
    Step Therapy

    Prerequisite therapy required for select indications

    Some indications require prerequisite therapy from specific drug classes (e.g., HRMs and other classes listed in product entries); provide documentation of prior agents tried as required.

    • Supply records of prior medications/trials that meet the product-specific prerequisite therapy requirements
    Documentation Required

    Required medical information — diagnosis and disease‑specific confirmatory tests (CGD, osteopetrosis)

    Provide required medical information with PAs: diagnosis, and for CGD a molecular genetic test identifying a gene-related pathogenic variant; for malignant osteopetrosis, radiographic (X-ray) imaging demonstrating skeletal features.

    • For CGD: include molecular genetic test confirming a pathogenic variant
    • For malignant osteopetrosis: include radiographic imaging demonstrating skeletal features
    Documentation Required

    Required diagnostic documentation — ALK, right‑heart cath and other molecular tests

    Required diagnostic documentation commonly includes diagnosis and supporting test results — examples: ALK status for ALK-targeted agents and right‑heart catheterization results for PAH confirmation.

    • Include ALK, ROS1, RET, IDH2, PDGFRA, or other mutation test results when indicated
    • Include right‑heart catheterization results for PAH/WHO Group 1 where required
    Documentation Required

    Haegarda — baseline functional C1‑INH and low serum C4 required

    For Haegarda, baseline functional C1‑INH protein level (<50% of normal) and low serum C4 levels are required to confirm HAE type I or II prior to authorization.

    • Provide baseline functional C1‑INH (<50% of normal) and baseline serum C4 levels
    Documentation Required

    Deferasirox — serum ferritin required

    Deferasirox PA requests must include a serum ferritin level to support iron‑chelation therapy.

    • Include current serum ferritin value with the PA submission
    Documentation Required

    Emgality — diagnosis and migraine days/month required

    Emgality PA requires documentation of diagnosis and the number of migraine headache days per month (≥4 days prior to initiating preventive therapy); document clinical benefit for continuation.

    • Document diagnosis of migraine
    • Document number of migraine headache days per month (≥4 for initiation)
    • For continuation, document clinical benefit from therapy
    Documentation Required

    Diagnosis and condition‑specific documentation required (e.g., erlotinib, everolimus, Fintepla)

    Provide diagnosis and condition‑specific documentation for agents such as erlotinib, everolimus, and Fintepla — include mutation status, histology, prior/concomitant therapies, or prior anticonvulsant trials as specified.

    • Include EGFR mutation results for erlotinib where indicated
    • Provide prior endocrine/systemic therapy documentation for everolimus when required
    • Document prior antiepileptic drug trials for Fintepla in Dravet or LGS
    Denial Risk

    Denial risk — missing diagnostic documentation or specialist prescriber

    Lack of required diagnostic documentation or lack of required specialist prescriber where specified may trigger denial of the PA request.

    • Ensure all required tests and specialist consultations are documented in the PA submission
    Denial Risk

    Denial risk — missing PA criteria or required medical information

    Failure to meet PA Criteria or to provide required medical information (per product entry) may result in denial.

    Denial Risk

    Respiratory exclusion for Inbrija — asthma/COPD may trigger denial

    Inbrija exclusion criteria include asthma, COPD, or other chronic underlying lung disease; presence of these conditions may result in denial.

    • Confirm absence of asthma, COPD, or other chronic underlying lung disease in documentation
    Denial Risk

    Ivermectin — diagnosis required to avoid denial

    Ivermectin requests may be denied if the diagnosis is not provided or does not meet the listed indications (e.g., pediculosis or scabies criteria); include diagnosis documentation.

    • Provide diagnosis consistent with approved indications (pediculosis or scabies) to support the PA
    Denial Risk

    Tolvaptan exclusion — deny if another tolvaptan product is being received

    Tolvaptan (Jynarque) requests may be denied if the patient is currently receiving another tolvaptan product; confirm no concurrent tolvaptan therapy and document renal function.

    • Confirm patient is not receiving another tolvaptan product
    • Provide renal function documentation to support ADPKD indication
    Coverage duration1 year
    inv-275: ALK-positive — definition and testing requirement
    DefinitionALK‑positive = presence of an ALK rearrangement/fusion detected by an approved test
    RequirementALK testing required for coverage of ALK‑targeted NSCLC indications
    Age noteNSCLC indications typically for patients 18 years and older per product entries
    inv-276: ROS1-positive — definition and testing requirement
    DefinitionROS1‑positive = ROS1 gene‑positive non‑small cell lung cancer detected by an approved test
    RequirementROS1 testing required for Augtyro/Ibtrozi NSCLC coverage
    Age noteNSCLC entries generally specify age 18 and older
    inv-277: NTRK gene fusion — tumor-agnostic genomic alteration definition
    DefinitionNTRK gene fusion = genomic neurotrophic tyrosine receptor kinase fusion detected by an approved test
    ScopeUsed as a tumor‑agnostic eligibility criterion for solid tumors and certain pediatric gliomas
    Disease extentTumor must be locally advanced/metastatic or resection would cause severe morbidity
    inv-279: HAE Type I/II — diagnostic lab thresholds (functional C1-INH <50% and low serum C4)
    HAE Type I/II diagnostic lab thresholdsFunctional C1‑INH protein < 50% of normal AND low baseline serum C4 levels per lab reference
    UseRequired to confirm HAE type I/II for prophylaxis and acute therapy approvals (e.g., Haegarda, icatibant)
    PrescriberPrescribed by or in consultation with an allergist/immunologist or HAE specialist
    inv-282: BRAF V600 mutation-positive — definition for targeted therapy
    DefinitionBRAF V600 mutation‑positive = tumor harboring a BRAF V600 activating mutation detected by an approved test
    RequirementBRAF V600 testing required for use of BRAF‑directed combinations (e.g., Cotellic + Zelboraf) or other indicated therapies
    IndicationsApplies to melanoma, selected CNS tumors and other specified indications per product criteria
    inv-284: Biallelic pathogenic CTNS variants — genetic confirmation for cystinosis (Cystagon)
    Genetic confirmationDiagnosis of nephropathic cystinosis requires genetic testing showing biallelic pathogenic or likely pathogenic CTNS variants
    Alternative labOr elevated white blood cell cystine concentration above the lab reference range
    PrescriberPrescribed by or in consultation with a nephrologist or metabolic disease specialist
    inv-290: All Medically-accepted Indications — policy stance repeated across multiple entries
    Policy stanceAll FDA‑approved indications or All medically‑accepted indications are covered when PA criteria are met (product‑specific)
    PA requirementPrior authorization is required for listed specialty products; approvals typically for 1 year unless specified otherwise
    Off‑label noteSome entries list limited medically‑accepted off‑label uses; off‑label coverage varies by product
    inv-293: High-risk medication (HRM) — definition and prescriber confirmation requirement
    DefinitionHigh‑risk medications (HRMs) require prescriber confirmation that risk vs benefit has been assessed prior to initiation/continuation
    Age considerationPatients <65 years generally approved; patients >=65 years require additional criteria
    DocumentationPrescriber must document assessment and meet indication‑specific step therapy/prior therapy requirements where listed
    inv-296: Chronic underlying lung disease — exclusion definition (asthma, COPD)
    DefinitionChronic underlying lung disease = asthma, COPD, or other chronic lung disease
    Exclusion impactPresence of these conditions is an exclusion for certain inhaled products (e.g., Inbrija) and may trigger denial
    Required documentationDiagnosis and concurrent medication use must be provided
    inv-297: Onychomycosis due to dermatophytes — diagnostic confirmation methods
    Diagnostic confirmation methodsOnychomycosis due to dermatophytes requires confirmation by KOH preparation, fungal culture, or nail biopsy
    Usage contextRequired as part of prior authorization for oral itraconazole (oral capsule) therapy
    Coverage durationsDuration varies by indication (e.g., 12 months for disseminated/CNS histo; others 6–12 months)
    inv-298: Primary immunodeficiency (PID) — Part B vs D determination per CMS guidance note
    PID contextIVIG (Gamunex‑C) used for primary immunodeficiency may require Part B vs Part D determination per CMS guidance when administered in the patient’s home
    Authorization durationAuthorization will be for 12 months when approved
    Required infoRequired medical information must be provided as listed in PA (diagnosis, prescriber, etc.)